Novartis AG (NOVN) — Stock analysis
CHFCurrent price
117,82 CHF
-0,44 CHF (-0.37%) today
Market signals
About Novartis AG
Novartis is one of the world's largest pharmaceutical companies, headquartered in Basel, Switzerland. Formed in 1996 by the merger of Ciba-Geigy and Sandoz. Main therapeutic areas are cardiovascular/renal-metabolism (Entresto for heart failure), neuroscience (Kesimpta for MS, Cosentyx), oncology and immunology. In 2023 it separated Sandoz (generics and biosimilars) into a standalone listed company. SMI component.
What does Novartis do?▾
Novartis develops innovative drugs in cardiovascular (Entresto, among the world's most prescribed heart failure drugs), immunology (Cosentyx for psoriasis and arthritis), oncology (Kymriah CAR-T, Kisqali) and neuroscience (Kesimpta). Since 2023 Sandoz (generics) is a separate company.
Which exchange is Novartis listed on?▾
Novartis is listed on the SIX Swiss Exchange with ticker NOVN. It is a member of the SMI (Swiss Market Index). It also has ADRs on NYSE with ticker NVS.
Does Novartis pay dividends?▾
Yes. It pays a progressively growing annual dividend. Yield is typically 3–4%.
Analyse this stock with AI
Create a free account and get 2 credits to generate a complete analysis.
Create account · 2 free credits